| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.mpspharmaa.com | |
| Market Cap | 6.13 Cr. | |
| Enterprise Value(EV) | 13.18 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.47 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.15 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 1.15 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 2.78 | Calculated using Price: 3.21 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.91 Cr. | 19,111,400 Shares |
| FaceValue | 10 | |
| About MPS Pharmaa Ltd. | ||
| Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products. | ||
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
+4.90% |
| 3 Month |
|
+9.93% |
| 6 Month |
|
+20.68% |
| 1 Year |
|
+52.86% |
| 2 Year |
|
+121.38% |
| 5 Year |
|
+68.95% |
| 10 Year |
|
-17.69% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -4.03 | -6.79 | -48.3 | -7.74 | -12.28 | -13.04 | -71.73 | -3.64 | -31.75 | |
| Return on Capital Employed (%) | 0.59 | -4.23 | -33.9 | -5.91 | -7.76 | -8.08 | -36.9 | -9.64 | -11.15 | |
| Return on Assets (%) | -2.01 | -3.91 | -29.85 | -4.32 | -6.79 | -6.87 | -31.87 | -1.32 | -10.33 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 19 | 19 | 12 | 11 | 10 | 8 | 4 | 4 | 3 | 2 | |
| Non Curr. Liab. | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |
| Curr. Liab. | 10 | 7 | 8 | 8 | 7 | 7 | 7 | 6 | 7 | 7 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 32 | 29 | 21 | 19 | 18 | 16 | 11 | 10 | 10 | 10 | |
| Non Curr. Assets | 15 | 15 | 14 | 13 | 12 | 11 | 9 | 8 | 8 | 8 | |
| Curr. Assets | 17 | 14 | 7 | 7 | 5 | 5 | 2 | 2 | 2 | 2 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 32 | 29 | 21 | 19 | 18 | 16 | 11 | 10 | 10 | 10 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 12 | 1 | 3 | 4 | 1 | 0 | |||||
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Total Income | 12 | 1 | 3 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Total Expenditure | -11 | -2 | -10 | -5 | -2 | -1 | -4 | -1 | -1 | -1 | |
| PBIDT | 1 | 0 | -7 | 0 | -1 | -1 | -4 | 0 | -1 | -1 | |
| Interest | -1 | 0 | |||||||||
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Exceptional Items | |||||||||||
| PAT | -1 | -1 | -7 | -1 | -1 | -1 | -4 | 0 | -1 | -1 | |
| Adjusted EPS | 0 | -1 | -4 | 0 | -1 | -1 | -2 | 0 | -1 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 5 | 2 | 1 | 0 | 0 | 1 | 0 | -1 | -4 | -1 | |
| Cash Fr. Inv. | -6 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | |
| Cash Fr. Finan. | 2 | -2 | -1 | -1 | 0 | 0 | -1 | 4 | 1 | ||
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Fri, 12 Apr 2024
Confirmation On Non Applicability Of The Criteria Specified Under SEBI Circular No. SEBI/HO/DDHS CIR/P/2018/144 Dated 26Th November 2018Read With Circular No. LIST/COMP/05/2019-20 Dated April 11 2019 Submission of the declaration that our Company " MPS Pharmaa Limited (formerly known as Advik Laboratories Limited) " does not fall under the category of Large Corporate (LC) as on 31st march 2024 . |
|
Fri, 12 Apr 2024
Submission Of Compliance Certificate Pursuant To Regulation 7 (3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Submission of compliance certificate pursuant to Regulation 7(3) of SEBI (LORD) 2015 |
|
Thu, 11 Apr 2024
Statement Of Investor Complaints For The Quarter Ended 31Stmarch 2024 Submission of investor complaint for the quarter ended 31st March 2024 |
| Mon, 08 Apr 2024 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Opening at High
|
Close Within 52 Week High Zone
|
